Adagene Inc (ADAG)vsModerna Inc (MRNA)
ADAG
Adagene Inc
$3.40
+2.72%
HEALTHCARE · Cap: $222.24M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 23881% more annual revenue ($2.23B vs $9.29M). MRNA leads profitability with a -141.4% profit margin vs -220.8%. ADAG earns a higher WallStSmart Score of 29/100 (F).
ADAG
Avoid29
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADAG.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 7333.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -144.5% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADAG
The strongest argument for ADAG centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 7333.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ADAG
The primary concerns for ADAG are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ADAG profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
ADAG is growing revenue faster at 7333.0% — sustainability is the question.
ADAG generates stronger free cash flow (-15M), providing more financial flexibility.
Bottom Line
ADAG scores higher overall (29/100 vs 21/100) and 7333.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?